Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335–1347 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Chen, L., Tao, X., Zeng, M., Mi, Y. & Xu, L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J. Hepatol. 80, e64–e66 (2023).

Article  PubMed  Google Scholar 

Han, D. W. et al. Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases. Int. J. Biol. Sci. 19, 3595–3613 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, X. et al. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc. Natl Acad. Sci. USA 114, 3181–3185 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Juanola, O., Martínez-López, S., Francés, R. & Gómez-Hurtado, I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int. J. Environ. Res. Public Health 18, 5227 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakurai, Y., Kubota, N., Yamauchi, T. & Kadowaki, T. Role of insulin resistance in MAFLD. Int. J. Mol. Sci. 22, 4156 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686–690 (2013).

Article  CAS  PubMed  Google Scholar 

Garcia-Martinez, I., Alen, R., Rada, P. & Valverde, A. M. Insights into extracellular vesicles as biomarker of NAFLD pathogenesis. Front. Med. 7, 395 (2020).

Article  Google Scholar 

Zhang, P., Watari, K. & Karin, M. Innate immune cells link dietary cues to normal and abnormal metabolic regulation. Nat. Immunol. 26, 29–41 (2025).

Article  PubMed  PubMed Central  Google Scholar 

Flück, C. E. & Pandey, A. V. in Genetic Steroid Disorders (eds New, M. I. et al.) 125–143 (Elsevier, 2014).

Waskell, L., Kim, J.-J. P. & Kim, J.-J. P. in Cytochrome P450 (ed. Ortiz de Montellano, P. R.) 33–68 (Springer, 2015).

Nurhafizuddin, M., Azizi, A., Ming, L. C. & Shafqat, N. In silico analysis of PORD mutations on the 3D structure of P450 oxidoreductase. Molecules 27, 46 (2022).

Article  Google Scholar 

Yablokov, E. O. et al. A large-scale comparative analysis of affinity, thermodynamics and functional characteristics of interactions of twelve cytochrome P450 isoforms and their redox partners. Biochimie 162, 156–166 (2019).

Article  CAS  PubMed  Google Scholar 

Pandey, A. V. & Flück, C. E. NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol. Ther. 138, 229–254 (2013).

Article  CAS  PubMed  Google Scholar 

Zhang, T. et al. Clinical and genetic analysis of cytochrome P450 oxidoreductase (POR) deficiency in a female and the analysis of a novel POR intron mutation causing alternative mRNA splicing. J. Assist. Reprod. Genet. 37, 2503–2511 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Bishop-Bailey, D., Thomson, S., Askari, A., Faulkner, A. & Wheeler-Jones, C. Lipid-metabolizing cyps in the regulation and dysregulation of metabolism. Annu. Rev. Nutr. 34, 261–279 (2014).

Article  CAS  PubMed  Google Scholar 

Santos, L. R. B. dos & Fleming, I. Role of cytochrome P450-derived, polyunsaturated fatty acid mediators in diabetes and the metabolic syndrome. Prostaglandins Other Lipid Mediat. 148, 106407 (2020).

Article  PubMed  Google Scholar 

Porter, T. D., Banerjee, S., Stolarczyk, E. I. & Zou, L. Suppression of cytochrome P450 reductase (POR) expression in hepatoma cells replicates the hepatic lipidosis observed in hepatic POR-null mice. Drug Metab. Disposition 39, 966–973 (2011).

Article  CAS  Google Scholar 

Pillai, V. C., Snyder, R. O., Gumaste, U., Thekkumkara, T. J. & Mehvar, R. Effects of transient overexpression or knockdown of cytochrome P450 reductase on reactive oxygen species generation and hypoxia reoxygenation injury in liver cells. Clin. Exp. Pharmacol. Physiol. 38, 846–853 (2011).

Article  CAS  PubMed  Google Scholar 

Harjumäki, R., Pridgeon, C. S. & Ingelman-Sundberg, M. CYP2E1 in alcoholic and non-alcoholic liver injury. Roles of ROS, reactive intermediates and lipid overload. Int. J. Mol. Sci. 22, 8221 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Ashino, T., Yamamoto, M. & Numazawa, S. Nrf2 antioxidative system is involved in cytochrome P450 gene expression and activity: a delay in pentobarbital metabolism in nrf2-deficient mice. Drug Metab. Disposition 48, 673–680 (2020).

Article  CAS  Google Scholar 

Koppula, P., Zhuang, L. & Gan, B. Cytochrome P450 reductase (POR) as a ferroptosis fuel. Protein Cell 12, 675–679 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou, Y. et al. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nat. Chem. Biol. 16, 302–309 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shoieb, S. M., El-Ghiaty, M. A., Alqahtani, M. A. & El-Kadi, A. O. S. Cytochrome P450-derived eicosanoids and inflammation in liver diseases. Prostaglandins Other Lipid Mediat. 147, 106400 (2020).

Article  CAS  PubMed  Google Scholar 

Hardwick, J. P. Cytochrome P450 Function and Pharmacological Roles in Inflammation and Cancer Vol. 74 (Academic, 2015).

Zordoky, B. & El-Kadi, A. Role of NF-kB in the regulation of cytochrome P450 enzymes. Curr. Drug Metab. 10, 164–178 (2009).

Article  CAS  PubMed  Google Scholar 

Li, Y. et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 23, 117 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Cherubini, A., Della Torre, S., Pelusi, S. & Valenti, L. Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease. Trends Mol. Med. 30, 1126–1136 (2024).

Article  CAS  PubMed  Google Scholar 

Kendall, T. J. et al. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nat. Med. 29, 2939–2953 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raverdy, V. et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat. Med. 30, 3624–3633 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen, Y., Bian, S. & Le, J. Molecular landscape and diagnostic model of MASH: transcriptomic, proteomic, metabolomic, and lipidomic perspectives. Genes 16, 399 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Govaere, O. et al. Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment. Biochem. Pharmacol. 228, 116249 (2024).

Article  CAS  PubMed  Google Scholar 

Zhang, H. et al. Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Sci. Rep. 5, 17671 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu, J. et al. Silybin regulates P450s activity by attenuating endoplasmic reticulum stress in mouse nonalcoholic fatty